Andrew Popplewell PhD

Andrew Popplewell Ph.D., Head, Antibody Discovery and Engineering, UCB Celltech. After studying for a BSc(Hons) at Edinburgh University and obtaining a PhD from Southampton University in protein engineering, Dr Popplewell held post-doctoral positions at both Edinburgh and Southampton before joining Celltech in 1993. During his 25 years at Celltech (since 2004 UCB Celltech), Dr Popplewell has played a role in developing their antibody humanisation and E. coli expression technologies and has worked on the approved medicines Cimzia and Besponsa, plus several other clinical candidates. He currently leads the V-Region Discovery and Engineering department, overseeing the identification, humanisation and characterisation of therapeutic antibodies and antibody research tools.